Analyst Charles Duncan works at CANTOR FITZGERALD and is focused on the Industrials sector with 594 price targets and ratings documented since 2009 spanning on 37 stocks. Previously, Charles Duncan worked at PIPER SANDLER. Analyst's average stock valuation to be materialised ratio is 64.39% with an average time for price targets to be met of 336.09 days.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences, Inc at 02-Nov-2022.
Charles Duncan best performing recommendations are on LUMO (LUMOS PHARMA INC.).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS, INC) at 4/15/2020. The price target of $13 was fulfilled within 9 days with a profit of $5.86 (82.07%) receiving and performance score of 91.19.
Average potential price target upside